BenevolentAI vs Nabla

Nabla has a disclosed valuation of $180M, while BenevolentAI's valuation is not publicly available, making a direct size comparison difficult. Nabla employs 80 people.

BenevolentAI has raised more in total funding at $292M, compared to Nabla's $30M — a gap of $262M. Combined, the two companies have completed 1 known funding rounds.

Nabla holds the higher Awaira Score at 73/100, compared to BenevolentAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 11-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.

BenevolentAI was founded first in 2013, giving it 5 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

BenevolentAI has approximately 100-500 employees, while Nabla has approximately 80. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, BenevolentAI and Nabla are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.